Evidence map›Paper›PMID 36343329›Full record

ArticlemAbs

Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics.

Florian Heinkel, Meghan M Verstraete, Siran Cao, Janessa Li, Patrick Farber, Elizabeth Stangle, Begonia Silva-Moreno, Fangni Peng, Surjit Dixit, Martin J Boulanger and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Florian HeinkelZymeworks Inc., Vancouver, BC, Canada.ORCID 0000-0002-2383-9330
Meghan M VerstraeteZymeworks Inc., Vancouver, BC, Canada.ORCID 0000-0003-0422-2826
Siran CaoZymeworks Inc., Vancouver, BC, Canada.
Janessa LiZymeworks Inc., Vancouver, BC, Canada.
Patrick FarberZymeworks Inc., Vancouver, BC, Canada.
Elizabeth StangleZymeworks Inc., Vancouver, BC, Canada.
Begonia Silva-MorenoZymeworks Inc., Vancouver, BC, Canada.
Fangni PengDepartment of Biochemistry and Microbiology; University of Victoria, Victoria, BC, Canada.
Surjit DixitZymeworks Inc., Vancouver, BC, Canada.
Martin J BoulangerDepartment of Biochemistry and Microbiology; University of Victoria, Victoria, BC, Canada.ORCID 0000-0001-6835-9309
Thomas Spreter Von KreudensteinZymeworks Inc., Vancouver, BC, Canada.
Eric Escobar-CabreraZymeworks Inc., Vancouver, BC, Canada.ORCID 0000-0002-2749-8860

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abbreviationsCE-SDS: capillary electrophoresis sodium dodecyl sulfate; DSC: differential scanning calorimetry; FACS: fluorescence-activated cell sorting; FSA: full-sized antibody; Her2: human epidermal growth factor receptor 2; MFI: mean fluorescent intensity; OAA: one-armed antibody; PBS: phosphate-buffered saline; PDB: Protein Data Bank; SEC: size-exclusion chromatography; prepSEC (preparative SEC); RMSD: root-mean-square deviation; RU: resonance units; SPR: surface plasmon resonance; TAA: tumor-associated antigen; WT: wild-type.

Indexed as

Immunoglobulin AChromatography, GelHumansImmunoglobulin Aantibody engineeringantibody stabilitybiophysical characterization of antibodybispecific antibodyFc engineeringheterodimeric antibodyIgA therapeuticsmultivalent scaffoldquality by design

Identifiers

PMID36343329
PMCPMC9645255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.